Skip to main content
Premium Trial:

Request an Annual Quote

Sygnis Licenses Amplification Buffer to Qiagen

NEW YORK (GenomeWeb News) – Sygnis Pharma today said that it has licensed to Qiagen rights to distribute a new amplification buffer for isothermal amplification.

Sygnis, which is based in both Madrid, Spain and Heidelberg, Germany, said that the new buffer, which is used in isothermal amplification, was developed in the lab of Margarita Salas at the Center for Molecular Biology - Severo Ochoa, Autonomous University of Madrid/ Spanish National Research Council (CSIC). Terms of the agreement were not disclosed.

The deal is the second signed between Sygnis and Qiagen over the past year. Last July, Sygnis inked an exclusive global license with Qiagen for distribution of its polymerase QualiPhi, an updated version of the phi 29 DNA polymerase.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.